Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma

甲磺酸伊马替尼治疗不能手术的黑色素瘤患者的 II 期研究

基本信息

  • 批准号:
    7925639
  • 负责人:
  • 金额:
    $ 22.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-06-15 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The rising incidence of melanoma and the lack of effective treatments for advanced disease represents an important public health problem. Recent studies have demonstrated that melanomas arising from skin on the palms and soles (acral melanomas), on mucosal membranes, and from skin with chronic sun-induced damage (CSD) have distinctive patterns of chromosomal alterations as compared with the more common subtypes of melanoma arising on skin without CSD. Unlike melanoma occurring on skin without CSD, these less common subtypes of melanoma are characterized by increased copy numbers or amplifications of the chromosome 4q12 locus, with an associated overexpression of the resident tyrosine kinase protein c-KIT and/or mutations of c-KIT. Among the several mutations of c-KIT identified in these melanomas are the activating mutations that, in other tumor types such as gastrointestinal stromal tumors (GIST), have been associated with sensitivity to treatment with small molecule inhibitors of c-KIT. Imatinib mesylate may offer this particular subset of melanoma patients a new therapeutic option. This application proposes to test the hypothesis that, in tumors with somatic alterations of c-KIT, imatinib mesylate will achieve an objective response rate of at least 30 percent. A Simon two-stage minimax study design will be utilized. A response rate of 10 percent or less will not be considered promising, and a 30 percent response rate will be considered promising. The probabilities of a type I and type II error are both set at 0.10. In the initial stage, 16 patients will be enrolled. If fewer than 2 patients achieve a response, the trial will be closed and imatinib mesylate deemed ineffective in this patient population. If 2 or more responses are observed, 9 additional patients will be accrued until a total of 25 evaluable patients have been accrued. If 5 or more responses are observed in the 25 patients, then imatinib mesylate will be considered worthy of further testing. This design yields at least a 90 percent probability of a positive result if the true response rate is greater than or equal to 30 percent. Patients will be enrolled from 3 local sites. All tumors will be screened using florescence in-situ hybridization (FISH) and DNA sequencing. Only patients with tumors harboring c-KIT amplifications or juxtamembrane domain mutations (the mutation site associated with the greatest sensitivity to imatinib mesylate in GIST) will be eligible. In addition, correlative studies will be performed on each patient's tumor including immunohistochemistry for CD117 as well as comparative genomic hybridization (CGH) to further assess for amplification at 4q12. If all eligibility criteria are met, patients will be prescribed 100 milligrams of imatinib mesylate capsules and will take 4 capsules twice a day (400 mg BID) by mouth on a continual basis. Imaging studies will be performed after 6 weeks of therapy. Patients who show a response or stable disease and have no evidence of progression will continue receiving daily imatinib mesylate. Dose reductions are allowed in the setting of toxicity. Imaging studies will be performed on an every 6 week schedule.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GARY K SCHWARTZ其他文献

GARY K SCHWARTZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GARY K SCHWARTZ', 18)}}的其他基金

P2 - Developing New Strategies for Targeting PDGFR/PI3K/AKT Pathways in Sarcoma
P2 - 制定针对肉瘤中 PDGFR/PI3K/AKT 通路的新策略
  • 批准号:
    7976102
  • 财政年份:
    2010
  • 资助金额:
    $ 22.81万
  • 项目类别:
Translational Research Studies in Clinical Trials of Novel Therapeutics for Sarco
Sarco 新型疗法临床试验的转化研究
  • 批准号:
    7942979
  • 财政年份:
    2009
  • 资助金额:
    $ 22.81万
  • 项目类别:
Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc
开发针对 Sarc 中 mTOR 和 IGF-1R/PI3K/Akt 通路的新策略
  • 批准号:
    8327269
  • 财政年份:
    2009
  • 资助金额:
    $ 22.81万
  • 项目类别:
Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc
开发针对 Sarc 中 mTOR 和 IGF-1R/PI3K/Akt 通路的新策略
  • 批准号:
    8812214
  • 财政年份:
    2009
  • 资助金额:
    $ 22.81万
  • 项目类别:
Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc
开发针对 Sarc 中 mTOR 和 IGF-1R/PI3K/Akt 通路的新策略
  • 批准号:
    7698068
  • 财政年份:
    2009
  • 资助金额:
    $ 22.81万
  • 项目类别:
Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc
开发针对 Sarc 中 mTOR 和 IGF-1R/PI3K/Akt 通路的新策略
  • 批准号:
    8192940
  • 财政年份:
    2009
  • 资助金额:
    $ 22.81万
  • 项目类别:
Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
甲磺酸伊马替尼治疗不能手术的黑色素瘤患者的 II 期研究
  • 批准号:
    7371810
  • 财政年份:
    2008
  • 资助金额:
    $ 22.81万
  • 项目类别:
Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
甲磺酸伊马替尼治疗不能手术的黑色素瘤患者的 II 期研究
  • 批准号:
    7640495
  • 财政年份:
    2008
  • 资助金额:
    $ 22.81万
  • 项目类别:
MSKCC Clinical Oncology Research Career Development Program
MSKCC 临床肿瘤学研究职业发展计划
  • 批准号:
    7678564
  • 财政年份:
    2006
  • 资助金额:
    $ 22.81万
  • 项目类别:
MSKCC Clinical Oncology Research Career Development Program
MSKCC 临床肿瘤学研究职业发展计划
  • 批准号:
    7485110
  • 财政年份:
    2006
  • 资助金额:
    $ 22.81万
  • 项目类别:

相似国自然基金

药用植物华泽兰中改善II型糖尿病并发抑郁症活性先导化合物的挖掘及其作用机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
脂肪干细胞外泌体调节Bax/BAK1-caspase-3/caspase8信号轴影响II型肺泡上皮细胞衰老在脓毒症肺损伤中的作用及机制
  • 批准号:
    MS25H010004
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
超长波长NIR-II 区有机探针的开发及在活体检测中的应用
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
αvβ3整合素靶向有机探针用于NIR-II FL/MRI双模态成像引导的三阴性乳腺癌光热治疗研究
  • 批准号:
    2025JJ81013
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
全钒液流电池负极V(II)/V(III)电化学氧化还原的催化机理研究
  • 批准号:
    2025JJ50094
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
1 类新药研发后补助(治疗用生物制品 1 类 MG-K10 人源化单抗注射液、II 期临床试验)
  • 批准号:
    2025JK2095
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
1 类新药研发后补助(治疗用生物制品 1 类MG-ZG122 人源化单抗注射液、II 期临床试验)
  • 批准号:
    2025JK2097
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
黏土矿物结构Fe(II)跨界面驱动氧化铁结合态有机质释放和转化机制
  • 批准号:
    2025JJ50205
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
有序组装型NIR-II荧光探针的构建及疾病辅助诊断应用
  • 批准号:
    2025JJ40014
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
NIR-II荧光内镜辅助胰腺癌术中肿瘤活性评估的可视化研究
  • 批准号:
    2025JJ50653
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目

相似海外基金

Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
  • 批准号:
    10481965
  • 财政年份:
    2024
  • 资助金额:
    $ 22.81万
  • 项目类别:
Embolosclerotherapy for leg venous malformations, Phase I/II prospective study
栓塞硬化疗法治疗腿部静脉畸形,I/II 期前瞻性研究
  • 批准号:
    23K07076
  • 财政年份:
    2023
  • 资助金额:
    $ 22.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
评估联合系统化疗和多轮内镜超声引导射频消融治疗胰腺癌的安全性和有效性的单组 II 期研究
  • 批准号:
    10743356
  • 财政年份:
    2023
  • 资助金额:
    $ 22.81万
  • 项目类别:
A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer
Th17诱导树突状细胞和派姆单抗联合治疗复发性上皮性卵巢癌患者的 I/II 期研究
  • 批准号:
    10564386
  • 财政年份:
    2023
  • 资助金额:
    $ 22.81万
  • 项目类别:
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
ASTX727 在 PRC2 缺失恶性周围神经鞘瘤 (MPNST) 患者中的 II 期研究
  • 批准号:
    10502752
  • 财政年份:
    2022
  • 资助金额:
    $ 22.81万
  • 项目类别:
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection
FDA 正在进行的一项噬菌体治疗慢性假体周围关节感染的 II/III 期临床研究中,磷壁酸糖基化在噬菌体活性和选择中的作用
  • 批准号:
    10704149
  • 财政年份:
    2022
  • 资助金额:
    $ 22.81万
  • 项目类别:
A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma
雷莫芦单抗和紫杉醇/扎尼达单抗治疗 HER2 过表达晚期胃食管腺癌的随机 II 期研究
  • 批准号:
    466229
  • 财政年份:
    2022
  • 资助金额:
    $ 22.81万
  • 项目类别:
    Operating Grants
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system
II 期研究评估 baricitinib 减少中枢神经系统 HIV 的有效性和安全性
  • 批准号:
    10681470
  • 财政年份:
    2022
  • 资助金额:
    $ 22.81万
  • 项目类别:
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection
FDA 正在进行的一项噬菌体治疗慢性假体周围关节感染的 II/III 期临床研究中,磷壁酸糖基化在噬菌体活性和选择中的作用
  • 批准号:
    10598830
  • 财政年份:
    2022
  • 资助金额:
    $ 22.81万
  • 项目类别:
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system
II 期研究评估 baricitinib 减少中枢神经系统 HIV 的有效性和安全性
  • 批准号:
    10484645
  • 财政年份:
    2022
  • 资助金额:
    $ 22.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了